Treatment suboptimal in AF

The finding is from 12-month follow-up data of nearly 700 Australians with AF and a CHA2DS2-VASc score of 2 or more enrolled as the first of five cohorts into the GARFIELD registry (Global Anticoagulant Registry in the Field). The registry, funded by Bayer and run by the Thrombosis Research Institute, London, began in 2009 with the first cohort enrolments commencing prior to marketing of novel anticoagulants, so the majority of assessed cases were on warfarin.

Dr Harry Gibbs, medical director of the vascular laboratory at The Alfred hospital, Melbourne, and GARFIELD Australian investigator, told a media briefing that data